GHK-CU is a prescription therapy used for skin health and collagen support.

Patients seeking support for skin health and collagen support may qualify after evaluation by a licensed provider.

Yes. Injectable GHK-Cu is a compounded prescription peptide dispensed pursuant to a valid prescription from a licensed healthcare provider. A telehealth consultation, informed consent, and full medical intake are required before dispensing to confirm clinical suitability and establish an individualized treatment protocol.

GHK-Cu has a well-established safety profile and a favorable reported profile in injectable use. Side effects are generally mild and may include injection site reactions (mild redness, bruising, or transient discomfort), temporary skin flushing or warmth consistent with local vasodilatory effects, mild headache reported occasionally, and transient fatigue during initial treatment days. Serious adverse effects have not been documented at therapeutic doses. Contact your provider immediately if you experience persistent injection site reactions, signs of systemic allergic response, or unusual neurological symptoms.

Injectable GHK-Cu is not appropriate for patients with active malignancy without thorough oncological evaluation, given its gene-modulating and angiogenic activity. Patients with Wilson's disease or other copper metabolism disorders must not use GHK-Cu, as it delivers bioavailable copper. Those with known sensitivity to benzyl alcohol — present in the bacteriostatic water diluent — should not use this formulation. It is not appropriate for patients who are pregnant or breastfeeding, or those under 18. Disclose your full history including any malignancy or copper-related conditions before starting.

Copper-chelating agents (D-penicillamine, trientine) used in conditions such as Wilson's disease will directly antagonize GHK-Cu's copper component — concurrent use is contraindicated without specialist guidance. High-dose antioxidant supplementation such as vitamin C or NAC may theoretically interact with GHK-Cu's copper-mediated redox activity at very high doses. Patients on systemic immunosuppressive therapy require individualized evaluation due to GHK-Cu's immune and inflammatory gene-modulating activity. Provide a complete medication list before beginning treatment.

Any history of malignancy requires oncological and provider review before starting. Copper metabolism disorders (Wilson's disease), autoimmune conditions, and significant cardiovascular, hepatic, or renal disease require individualized assessment. All clinical use of injectable GHK-Cu is off-label. Your provider requires a complete medical history before prescribing and will determine whether GHK-Cu is appropriate given your individual health profile.